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BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR),
and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy.
METHODS: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR
inhibitor, or prior anti-PD-1/PD-L1 therapy.
RESULTS: For the prior sunitinib subgroup (N= 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR
0.43, 95% CI 0.32–0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47–0.93). For the
prior pazopanib subgroup (N= 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI
0.45–0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42–1.04). For prior anti-PD-1/
PD-L1 therapy (N= 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07–0.65),
ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21–1.52).
CONCLUSIONS: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC,
irrespective of prior therapy, including checkpoint inhibitor therapy.
British Journal of Cancer (2018) 119:663–669; https://doi.org/10.1038/s41416-018-0164-0
INTRODUCTION
During the past decade, treatments for advanced renal cell
carcinoma (RCC) have evolved dramatically with the approval of
multiple targeted therapies, including VEGF receptor tyrosine
kinase inhibitors (VEGFR TKIs; sorafenib, sunitinib, pazopanib,
axitinib), the VEGF-targeted monoclonal antibody bevacizumab,
and mTOR inhibitors (temsirolimus and everolimus).1,2 Although
survival of patients with advanced RCC has improved since the
introduction of targeted therapy, current treatments are rarely
curative and often result in therapeutic resistance.1 Long-term
disease management has relied on sequential treatment with
VEGF-targeted agents and mTOR inhibitors, with sunitinib and
pazopanib as the most commonly used first-line therapies.1,3,4
Recent studies of nivolumab,5 cabozantinib,6,7 and lenvatinib in
combination with everolimus8 supported approval of these
regimens for previously treated patients; both nivolumab and
cabozantinib demonstrated improved survival versus everolimus.
Given the availability of many treatment options, it is important to
consider the effect of prior therapy on patient outcomes to
maximise clinical benefit in the second-line setting and beyond.
Cabozantinib, an orally bioavailable TKI, inhibits targets
implicated in the pathogenesis and progression of RCC, including
VEGFRs, MET, and AXL.9,10 Resistance to VEGF pathway inhibition
is associated with activation of MET and AXL signalling, and
cabozantinib overcomes sunitinib resistance in preclinical RCC
models.9 The pivotal phase 3 METEOR trial evaluated cabozantinib
versus everolimus in patients with advanced RCC following VEGFR
TKI therapy.6,7 Compared with everolimus, cabozantinib demon-
strated improved progression-free survival (PFS), overall survival
(OS), and objective response rate (ORR). Here we describe
subgroup analyses of clinical outcomes in the METEOR trial based
on prior therapy with VEGFR TKIs and PD-1/PD-L1 immune
checkpoint inhibitors.
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METHODS
Study design and patients
The study design and methods for the international, randomised,
open-label, phase 3 METEOR trial (NCT01865747) have been
previously reported.6,7 Key eligibility criteria included a diagnosis
of RCC with a clear-cell component, measurable disease per
response evaluation criteria in solid tumours (RECIST) v1.1,11 and
prior treatment with ≥1 VEGFR TKI. Radiographic progression
during or within 6 months of the most recent VEGFR TKI regimen
was required. The last dose of VEGFR TKI must have been received
between 6 months and 2 weeks before randomisation. Previous
treatment with immune checkpoint inhibitors was permitted, and
treatment must have been stopped >4 weeks before randomisa-
tion. Other allowed prior therapies included interferon-α, inter-
leukin-2, bevacizumab, cytotoxic chemotherapy, nephrectomy,
and radiotherapy; there was no limit to the number of prior
therapies. Prior therapy with cabozantinib or an mTOR inhibitor
was not permitted. Karnofsky Performance Status ≥ 70% and
adequate organ function were required.
Six hundred and fifty-eight patients were randomised 1:1 to
receive cabozantinib (60 mg once daily) or everolimus (10 mg
once daily). Stratification was by Memorial Sloan Kettering Cancer
Table 1. Baseline characteristics













Median age, years (range) 62.0 (37–79) 62.0 (31–81) 63.0 (38–86) 61.0 (36–84) 63.5 (47–81) 61.0 (37–84)
Sex, n (%)
Male 106 (79) 95 (72) 68 (77) 64 (77) 13 (72) 11 (79)
Female 29 (21) 36 (27) 20 (23) 19 (23) 5 (28) 3 (21)
Missing 0 1 (1) 0 0 0 0
Enrollment region, n (%)
Europe 72 (53) 66 (50) 34 (39) 34 (41) 6 (33) 6 (43)
North America 45 (33) 43 (33) 35 (40) 32 (39) 11 (61) 7 (50)
Asia Pacific 18 (13) 22 (17) 13 (15) 13 (16) 1 (6) 1 (7)
Latin America 0 1 (1) 6 (7) 4 (5) 0 0
ECOG performance statusa, n (%)
0 95 (70) 87 (66) 66 (75) 49 (59) 12 (67) 9 (64)
1 40 (30) 45 (34) 22 (25) 34 (41) 6 (33) 5 (36)
MSKCC risk group, n (%)
Favourable 55 (41) 60 (45) 40 (45) 35 (42) 5 (28) 6 (43)
Intermediate 63 (47) 58 (44) 39 (44) 37 (45) 9 (50) 7 (50)
Poor 17 (13) 14 (11) 9 (10) 11 (13) 4 (22) 1 (7)
Sum of target lesion
diameters, mm (range)
60.1 (0–291) 60.6 (0–231) 66.7 (0–240) 60.7 (0–217) 92.0 (0–194) 83.0 (16–190)
Metastatic sites per IRC, n (%)
Lung 80 (59) 88 (67) 62 (70) 54 (65) 10 (56) 11 (79)
Liver 43 (32) 55 (42) 22 (25) 16 (19) 6 (33) 4 (29)
Bone 27 (20) 23 (17) 20 (23) 18 (22) 5 (28) 4 (29)
Lymph node 83 (61) 78 (59) 48 (55) 47 (57) 11 (61) 10 (71)
Number of prior VEGFR TKIs, n (%)
1 135 (100) 132 (100) 88 (100) 83 (100) 7 (39) 8 (57)
≥2 0 0 0 0 11 (61) 6 (43)
Prior systemic therapy, n (%)
Sunitinib 135 (100) 132 (100) 0 0 12 (67) 9 (64)
Pazopanib 0 0 88 (100) 83 (100) 11 (61) 6 (43)
Axitinib 0 0 0 0 5 (28) 3 (21)
Sorafenib 0 0 0 0 1 (6) 2 (14)
Bevacizumab 0 3 (2) 1 (1) 3 (4) 1 (6) 1 (7)
Interleukins 7 (5) 7 (5) 4 (5) 7 (8) 2 (11) 0
Interferons 4 (3) 7 (5) 6 (7) 5 (6) 1 (6) 0
Anti–PD- 1/PD-L1 5 (4) 5 (4) 2 (2) 3 (4) 18 (100) 14 (100)
Radiotherapy, n (%) 39 (29) 41 (31) 35 (40) 26 (31) 6 (33) 5 (36)
Nephrectomy, n (%) 116 (86) 112 (85) 76 (86) 65 (78) 16 (89) 11 (79)
ECOG Eastern Cooperative Oncology Group, IRC independent radiology committee, MSKCC Memorial Sloan Kettering Cancer Center, TKI tyrosine kinase
inhibitor. aBased on Karnofsky Performance Status score
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Center (MSKCC) risk group12 (favourable, intermediate, or poor)
and number of prior VEGFR TKIs (1 or ≥2). Dose reductions (to 40
mg and 20mg for cabozantinib or to 5 mg and 2.5 mg for
everolimus) were allowed to manage adverse events (AEs).
The study was conducted in accordance with the Good Clinical
Practice guidelines and the Declaration of Helsinki. The protocol
was approved by the ethics committee or institutional review
board at each centre, and all patients provided written informed
consent.
Assessments
Measures of clinical outcome included the primary endpoint of
PFS, the secondary endpoints of ORR and OS, and safety. Tumour
assessment by computed tomography or magnetic resonance
imaging was performed at screening, every 8 weeks for the first
12 months, and every 12 weeks thereafter. Tumour response was
assessed by RECIST v1.1.11 PFS was per independent radiology
committee (IRC). Safety was evaluated every 2 weeks for the first
8 weeks and every 4 weeks thereafter until treatment discontinua-
tion. A follow-up visit was scheduled 30 days after treatment
discontinuation. AEs were reported according to National Cancer
Institute Common Terminology Criteria for Adverse Events, v4.0.13
Data cut-off dates were 22 May 2015 for PFS and ORR and 31
December 2015 for OS and safety.
Statistical analysis
Efficacy and safety outcomes for METEOR, including hazard ratios
(HRs) for PFS and OS for subgroups based on prior therapy, have
been previously reported.6,7 Efficacy analyses used all randomised
patients, and safety analyses used all patients who received ≥1
dose of study drug. PFS and OS were assessed by the
Kaplan–Meier method. No adjustments for multiplicity were made
for subgroup analyses. Confidence intervals are considered
descriptive, and HRs are unstratified.
PFS, ORR, and OS were evaluated in subgroups defined by
number of prior VEGFR TKI therapies (1 or ≥2) and duration of
treatment with first VEGFR TKI (≤6 or >6 months). PFS, ORR, OS,
and safety were evaluated in subgroups defined by treatment
with sunitinib or pazopanib as the only prior VEGFR TKI and by
treatment with prior anti-PD-1/PD-L1. Subgroup analyses of
efficacy were prespecified except those based on prior treatment
with sunitinib or pazopanib.
RESULTS
Patients
From 8 August 2013 to 24 November 2014, 658 patients were
randomised 1:1 to receive cabozantinib (N= 330) or everolimus
(N= 328). Two hundred thirty-five (71%) patients in the cabo-
zantinib arm and 229 (70%) patients in the everolimus arm had
received only one prior VEGFR TKI. One hundred thirty-five (41%)
patients in the cabozantinib arm and 132 (40%) in the everolimus
arm had received sunitinib as their only prior VEGFR TKI, and 88
(27%) in the cabozantinib arm and 83 (25%) in the everolimus arm
had received prior pazopanib only.
Thirty-two (4.9%) patients had received prior anti-PD-1/PD-L1
therapy, 18 (5.4%) in the cabozantinib arm and 14 (4.3%) in the
everolimus arm (Supplement Figure S1). Thirty-one patients had
received nivolumab and one had received atezolizumab (Supple-
ment Table S1). Most had received anti-PD-1/PD-L1 therapy in the
second-line setting or later: 16 patients in the cabozantinib arm
and 12 in the everolimus arm. Six patients in the cabozantinib arm
and seven in the everolimus arm had received nivolumab as their
most recent prior therapy. The median duration of prior therapy
with PD-1/PD-L1 inhibitors was 18.0 weeks (range 4.4–62.6 weeks,
N= 31; duration missing for one patient). Forty-nine (7.4%)
patients had received prior IL-2 therapy, 20 (6.1%) in the
cabozantinib arm and 29 (8.8%) in the everolimus arm.
Demographics and baseline characteristics were generally
balanced between treatment groups for patients who had received
sunitinib or pazopanib as the only prior VEGFR TKI (Table 1),
although for the prior pazopanib subgroup, patients in the
cabozantinib group had better ECOG performance status compared
with the everolimus group (75% versus 59% had ECOG PS 0). In the
prior anti-PD-1/PD-L1 subgroup, patients in the cabozantinib group
had less favourable MSKCC risk status compared with the everolimus
group (28% versus 43% had favourable risk and 22% versus 7% had
poor risk for cabozantinib versus everolimus) and had received ≥2
VEGFR TKI therapies more frequently (61% versus 43%, respectively).
As of the 31 December 2015 cut-off date for OS, the number of
patients who continued to receive study treatment with
cabozantinib versus everolimus was 30 (22%) versus 9 (7%) for
prior sunitinib, 16 (18%) versus 7 (8%) for prior pazopanib, and 6
(33%) versus 1 (7%) for prior anti-PD-1/PD-L1.
Efficacy outcomes
Number and duration of prior VEGFR TKI therapies. For patients
who had received only one prior VEGFR TKI, median PFS was



























Prior sunitinib only Prior pazopanib only Prior anti–PD-1/PD-L1a b c





































































Time (months) Time (months) Time (months)
Fig. 1 Kaplan–Meier analysis of progression-free survival. Disease progression was assessed by an independent radiology committee. Data
cut-off date: 22 May 2015. CI confidence interval, NR not reached
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0.52, 95% CI 0.41–0.66), ORR per IRC was 17% versus 3%, and
median OS was 21.4 versus 16.5 months (HR 0.65, 95% CI
0.50–0.85) (Supplement Table S2). For patients who had received
≥2 VEGF TKIs, median PFS was 7.4 months for cabozantinib versus
4.0 months for everolimus (HR 0.51, 95% CI 0.35–0.74), ORR per IRC
was 17% versus 4%, and median OS was 20.8 versus 17.2 months
(HR 0.73, 95% CI 0.48–1.10).
Efficacy outcomes were also assessed based on treatment
duration with first VEGFR TKI therapy. For patients previously
treated ≤6 months, median PFS was 5.6 months for cabozantinib
versus 3.7 months for everolimus (HR 0.62, 95% CI 0.44–0.89), ORR
per IRC was 14% versus 4%, and median OS was 21.3 versus
13.8 months (HR 0.69, 95% CI 0.47–1.01) (Supplement Table S2). For
patients previously treated >6 months, median PFS was 9.0 months
for cabozantinib versus 3.9 months for everolimus (HR 0.48, 95% CI
0.38–0.62), ORR per IRC was 19% versus 3%, and median OS was
22.0 versus 18.4 months (HR 0.69, 95% CI 0.52–0.90).
Type of prior VEGFR TKI therapy. For patients treated with sunitinib
as the only prior VEGFR TKI, median PFS was 9.1 months for
cabozantinib versus 3.7 months for everolimus (HR 0.43, 95% CI
0.32–0.59) (Fig. 1), ORR per IRC was 16% versus 3% (Table 2), and
median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47–0.93)
(Fig. 2).
For patients treated with pazopanib as the only prior VEGFR TKI,
median PFS was 7.4 months for cabozantinib versus 5.1 months
for everolimus (HR 0.67, 95% CI 0.45–0.99) (Fig. 1), ORR per IRC was
19% versus 4% (Table 2), and median OS was 22.0 versus
17.5 months (HR 0.66, 95% CI 0.42–1.04) (Fig. 2).
As of 31 December 2015 cut-off date for OS, the percentage of
patients who had received subsequent anticancer therapy was
similar in the two treatment groups for the prior sunitinib (48%
for cabozantinib versus 55% for everolimus) and prior pazopanib
subgroups (52% versus 53%, respectively) (Supplement
Table S3).
Prior therapy with Anti-PD-1/PD-L1 or IL-2. Checkpoint inhibitor
therapy is relatively new to the RCC treatment landscape;
however, some patients enrolled in METEOR had received anti-
PD-1/PD-L1 antibodies in clinical trials. For these patients, median
PFS was not reached for cabozantinib compared with 4.1 months
for everolimus (HR 0.22; 95% CI 0.07–0.65) (Fig. 1), and ORR per IRC
was 22% versus 0% (Table 2). Median OS was not reached for
cabozantinib versus 16.3 months for everolimus (HR 0.56; 95% CI
0.21–1.52) (Fig. 2). As of 22 May 2015, cut-off date for PFS, nine out
of 18 patients in the cabozantinib group remained on study
treatment without experiencing progression; four patients had an
ongoing objective response. In the everolimus group, no patients
remained on study treatment without experiencing progression
(Fig. 3). As of 31 December 2015, cut-off date for OS, the
percentages of patients who had received subsequent anticancer
therapy were 33% in the cabozantinib group and 71% in the
Table 2. Tumour response per Independent Radiology Committee















16 (11–24) 3 (1–8) 19 (12–29) 4 (1–10) 22 (6–48) 0
Best overall response, n (%)
Confirmed partial
response
22 (16) 4 (3) 17 (19) 3 (4) 4 (22) 0
Stable disease 89 (66) 75 (57) 57 (65) 55 (66) 9 (50) 9 (64)
Progressive disease 16 (12) 46 (35) 12 (14) 18 (22) 2 (11) 4 (29)
Not evaluable or
missingb
8 (6) 7 (5) 2 (2) 7 (8) 3 (17) 1 (7)
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Fig. 2 Kaplan–Meier analysis of overall survival. Data cut-off date: 31 December 2015. CI confidence interval, NR not reached
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everolimus group (Supplement Table S3).
Efficacy outcomes were also assessed for patients who had
received prior therapy with IL-2 (N= 49). Median PFS was
7.2 months for cabozantinib versus 5.5 months for everolimus
(HR 0.57, 95% CI 0.27–1.19), ORR per IRC was 10% versus 3%, and
median OS was not reached for either treatment (HR 0.75, 95% CI
0.27–2.08) (Supplement Table S4).
Safety
The median duration of exposure was 9.2 months for cabozantinib
and 4.3 months for everolimus in the prior sunitinib subgroup,
7.7 months and 4.2 months in the prior pazopanib subgroup, and
11.4 and 4.6 months in the prior anti-PD-1/PD-L1 subgroup,
respectively (Supplement Table S5).
Grade 3/4 AEs were reported in 67% of cabozantinib-treated
patients and 61% of everolimus-treated patients in the prior
sunitinib subgroup; 73% and 62% of patients in the prior
pazopanib subgroup; and 83% and 64% of patients in the prior
anti-PD-1/PD-L1 subgroup (Table 3). Patients who had received
sunitinib versus pazopanib as the only prior VEGFR TKI had a
higher incidence (≥5% difference) of the following grade 3/4 AEs:
diarrhoea (15% versus 9%), nausea (7% versus 1%), and anaemia
(8% versus 3%) for cabozantinib-treated patients, and anaemia
(18% versus 9%) for everolimus-treated patients. No grade 3/4 AEs
were ≥5% higher in patients who had received prior pazopanib
versus prior sunitinib. The incidence of AEs related to hepatotoxi-
city (laboratory assessments of liver function) was similar for the
prior sunitinib and prior pazopanib subgroups: there were no
differences ≥5% in either all grade or grade 3/4 events between
the subgroups (Supplement Table S6).
DISCUSSION
The phase 3 METEOR trial compared the efficacy and safety of
cabozantinib with everolimus in patients with advanced RCC
following VEGFR TKI therapy. Subgroup analyses reported here are
consistent with results from the overall study population with
observed improvements in PFS, ORR, and OS for cabozantinib
compared with everolimus irrespective of prior therapy.
Limitations of these analyses include the small size of the subgroups,






On treatment with response
Censored without progression at data cutoff
Censored with ongoing response at data cutoff
Censored for use of non-study anticancer therapy
PFS event
Fig. 3 Progression-free survival and response in the prior anti-PD-1/PD-L1 subgroup. Disease progression was assessed by an independent
radiology committee. Data cut-off date: 22 May 2015
Table 3. All causality grade 3/4 adverse events













Any, n (%) 91 (67) 80 (61) 64 (73) 50 (62) 15 (83) 9 (64)
Hypertension 22 (16) 6 (5) 14 (16) 2 (2) 4 (22) 0
Diarrhoea 21 (15) 4 (3) 8 (9) 0 2 (11) 0
Fatigue 15 (11) 9 (7) 6 (7) 8 (10) 5 (28) 2 (14)
PPE 11 (8) 0 9 (10) 2 (2) 3 (17) 1 (7)
Anaemia 11 (8) 23 (18) 3 (3) 7 (9) 2 (11) 2 (14)
Nausea 10 (7) 0 1 (1) 1 (1) 0 0
Hypomagnesemia 8 (6) 0 3 (3) 0 0 0
Hypokalaemia 8 (6) 2 (2) 2 (2) 3 (4) 0 0
Hyponatraemia 6 (4) 2 (2) 3 (3) 0 1 (6) 0
Asthaenia 5 (4) 3 (2) 2 (2) 3 (4) 2 (11) 0
Hyperglycaemia 0 6 (5) 2 (2) 3 (4) 0 0
Events that occurred at ≥ 5% frequency in either treatment arm of the overall safety population are summarised. PPE palmar-plantar erythrodysesthesia
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the use of descriptive statistics, and the post hoc nature of the
analyses based on prior treatment with sunitinib or pazopanib.
Historically, sequential therapy with VEGFR TKIs and mTOR
inhibitors was the standard of care for advanced RCC, with
sunitinib and pazopanib as preferred first-line agents and ever-
olimus and axitinib as standard second-line therapies.1,3,4 The AXIS
trial established axitinib as the preferred second-line VEGFR TKI
based on improved PFS compared with sorafenib; however, OS
was not significantly different for axitinib versus sorafenib.14 For
the subgroup of patients who had received prior sunitinib, median
PFS for axitinib was 4.8 months (HR versus sorafenib 0.74, 95% CI
0.57–0.96), and median OS was 15.2 months (HR 1.00, 95% CI
0.78–1.27).14
In the METEOR trial, PFS, ORR, and OS were improved for
cabozantinib versus everolimus with either sunitinib or pazopanib
as the only prior VEGFR TKI. These favourable results in VEGFR TKI-
refractory disease support the hypothesis that the clinical activity
of cabozantinib in RCC may result from combined inhibition of
VEGFRs and additional targets, such as MET and AXL, that are not
inhibited by other VEGFR TKIs.
Improved OS and investigator-assessed ORR have also been
reported for nivolumab compared with everolimus for subgroups
based on prior VEGFR TKI therapy in the CheckMate 025 trial.15
Median OS for nivolumab after sunitinib was 23.6 months (HR
0.81, 95% CI 0.64–1.04), and median OS for nivolumab after
pazopanib was not reached (HR 0.60, 95% CI 0.42–0.84). However,
subgroups in the nivolumab study were defined differently from
those in current study in that sunitinib or pazopanib could have
been either the first or second VEGFR TKI therapy in the
CheckMate 025 analysis.
Although limited data are available regarding the efficacy of
subsequent treatments for RCC following immune checkpoint
therapy, VEGFR TKIs appear to have clinical activity in this
setting.16,17 While only 5% of patients enrolled in METEOR had
received prior checkpoint inhibitor therapy, outcomes for this
subpopulation are clinically relevant, given the evolving role of
immuno-oncology agents in RCC, including ongoing phase 3 trials
in the first-line setting. In the prior anti-PD-1/PD-L1 subgroup,
cabozantinib treatment was associated with improved PFS (HR
0.22, 95% CI 0.07–0.65), OS (HR 0.56, 95% CI 0.21–1.52), and ORR,
as well as a higher rate of durable responses compared with
everolimus. Compared with the everolimus group, patients in the
cabozantinib group had less favourable MSKCC risk status, had
received ≥2 prior VEGFR TKI therapies more frequently, and had
received subsequent anticancer therapy less frequently. None-
theless, cabozantinib demonstrated an apparent clinical benefit
compared with everolimus in this subpopulation of third or later
line patients who had received both VEGFR TKI and checkpoint
inhibitor therapy. Resistance to PD-1/PD-L1 inhibition has been
associated with increased expression of immunosuppressive and
pro-angiogenic cytokines and transcription factors that promote
epithelial-mesenchymal transition.18,19 Cabozantinib inhibits key
mediators of both angiogenesis (VEGF receptors) and epithelial-
mesenchymal transition (MET and AXL) which may partially
account for its clinical activity after prior anti-PD-1/PD-L1 therapy.
Moreover, cabozantinib promotes a more immune permissive
tumour microenvironment,20 which may help overcome resis-
tance to checkpoint inhibitors.
Current guidelines for advanced RCC recommend cabozantinib
and nivolumab as second-line treatments after VEGFR-targeted
therapy based on improved OS compared with everolimus; both
agents are category 1 (preferred) by the National Comprehensive
Cancer Network2 and recommended with a survival advantage by
the European Association of Urology.21 Although no high-level
evidence is available regarding subsequent therapy after either
agent, subgroup analyses reported here suggest that cabozantinib
is clinically active following sequential therapy with VEGFR TKIs
and checkpoint inhibitors.
The types of grade 3/4 AEs reported across the prior therapy
subgroups were generally consistent with those observed for
the overall study population. For cabozantinib-treated patients,
some events, such as diarrhoea, nausea, and anaemia, were
reported at a higher rate (≥5% difference) for patients previously
treated with sunitinib compared with pazopanib, suggesting
that first-line VEGFR TKI therapy may influence the tolerability of
subsequent treatment with cabozantinib. Although pazopanib is
associated with a higher incidence of hepatoxicity than
sunitinib,22 no difference in the incidence of AEs related to
liver function was noted between the prior pazopanib and prior
sunitinib subgroups. This result is consistent with previous
reports that pazopanib-induced transaminitis is reversible.23 A
higher percentage of cabozantinib-treated patients experienced
grade 3/4 AEs in the prior anti-PD-1/PD-L1 subgroup compared
with the overall study population (83% versus 71%).24 This
difference may be related to the longer treatment duration in
the anti-PD-1/PD-L1 subgroup compared with the overall study
population (median of 11.4 versus 8.3 months), the poorer
prognostic status of patients in the anti-PD-1/PD-L1 subgroup,
or the small subgroup size.
Sequencing strategies for advanced RCC will continue to
evolve with the approval of cabozantinib and various immuno-
oncology combinations as first-line regimens. The randomised
phase 2 CABOSUN trial (NCT01835158) demonstrated that
cabozantinib treatment significantly improved PFS and ORR
versus sunitinib in previously untreated intermediate or poor
risk patients.25 In addition, results from the phase 3 CheckMate
214 trial (NCT02231749) demonstrated a significant improve-
ment in OS for the combination of nivolumab and ipilimumab
versus sunitinib in previously untreated patients of intermediate
or poor risk.26 Several other phase 3 studies are exploring
combinations of checkpoint inhibitors with antiangiogenic
agents,1 including the combination of cabozantinib with
nivolumab versus sunitinib (NCT03141177). With the anticipated
movement of immuno-oncology combinations into the first-line
setting, additional studies will be necessary to evaluate the
clinical impact of subsequent therapy with targeted agents
including cabozantinib.
In conclusion, cabozantinib, a second-line standard of care for
advanced RCC, demonstrated improvements in PFS, ORR, and OS
compared with everolimus regardless of the number, duration, or
type of prior VEGFR TKI therapies. Cabozantinib treatment was
also associated with improved clinical outcomes in patients who
had received both VEGFR TKI therapy and an immune checkpoint
inhibitor. These results highlight the broad clinical utility of
cabozantinib for previously treated patients with advanced RCC,
irrespective of prior therapy.
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